In patients with multiple sclerosis (MS), grey matter damage is widespread and might underlie many of the clinical symptoms, especially cognitive impairment. This relation between grey matter damage and cognitive impairment has been lent support by findings from clinical and MRI studies. However, many aspects of cognitive impairment in patients with MS still need to be characterised. Standardised neuropsychological tests that are easy to administer and sensitive to disease-related abnormalities are needed to gain a better understanding of the factors affecting cognitive performance in patients with MS than exists at present. Imaging measures of the grey matter are necessary, but not sufficient to fully characterise cognitive decline in MS. Imaging measures of both lesioned and normal-appearing white matter lend support to the hypothesis of the existence of an underlying disconnection syndrome that causes clinical symptoms to trigger. Findings on cortical reorganisation support the contribution of brain plasticity and cognitive reserve in limiting cognitive deficits. The development of clinical and imaging biomarkers that can monitor disease development and treatment response is crucial to allow early identification of patients with MS who are at risk of cognitive impairment.

Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis / Rocca, Maria A; Amato, Maria P; De Stefano, Nicola; Enzinger, Christian; Geurts, Jeroen J; Penner, Iris-K; Rovira, Alex; Sumowski, James F; Valsasina, Paola; Filippi, Massimo. - In: LANCET NEUROLOGY. - ISSN 1474-4422. - ELETTRONICO. - 14:(2015), pp. 302-317. [10.1016/S1474-4422(14)70250-9]

Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis

Amato, Maria P;
2015

Abstract

In patients with multiple sclerosis (MS), grey matter damage is widespread and might underlie many of the clinical symptoms, especially cognitive impairment. This relation between grey matter damage and cognitive impairment has been lent support by findings from clinical and MRI studies. However, many aspects of cognitive impairment in patients with MS still need to be characterised. Standardised neuropsychological tests that are easy to administer and sensitive to disease-related abnormalities are needed to gain a better understanding of the factors affecting cognitive performance in patients with MS than exists at present. Imaging measures of the grey matter are necessary, but not sufficient to fully characterise cognitive decline in MS. Imaging measures of both lesioned and normal-appearing white matter lend support to the hypothesis of the existence of an underlying disconnection syndrome that causes clinical symptoms to trigger. Findings on cortical reorganisation support the contribution of brain plasticity and cognitive reserve in limiting cognitive deficits. The development of clinical and imaging biomarkers that can monitor disease development and treatment response is crucial to allow early identification of patients with MS who are at risk of cognitive impairment.
2015
14
302
317
Goal 3: Good health and well-being for people
Rocca, Maria A; Amato, Maria P; De Stefano, Nicola; Enzinger, Christian; Geurts, Jeroen J; Penner, Iris-K; Rovira, Alex; Sumowski, James F; Valsasina,...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1121053
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 421
  • ???jsp.display-item.citation.isi??? 382
social impact